drugset / Trial / NCT00917150
To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To investigate the efficacy and safety of OPC-6535 in COPD patients, using the measurement of trough FEV1 over time as the primary endpoint.
Timeline
- Start
- 2009-03
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tetomilast | Small molecule | 12.5 mg | Oral |
| Subject | Tetomilast | Small molecule | 25 mg | Oral |
| Subject | Tetomilast | Small molecule | 50 mg | Oral |